Skip to content

Oral L-tyrosin for reversing gray hair; a clinical trial

The effect of supplementary oral L-tyrosin plus other essential elements (Dr Daniel capsule for gray hair) on reversing gray hair

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613001277730
Enrollment
15
Registered
2013-11-19
Start date
2013-12-31
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Previously it has been found that a tyrosine kinase inhibitor can reverse gray hairs of receivers. Tyrosine is an important precursor of melanin, an agent that directly produces hair color. This study for the first time investigates the effect of oral L-tyrosin (plus other important factors in the metabolism of melanin) in possible reversing of gray hair.

Interventions

Three groups of normal men with gray hair (total=15) will receive daily oral L-tyrosin 500 mg or 3000 mg daily plus other essential elements including 50 mg (in cases on 500 mg L-tyrosin) or 300 mg (in cases on 3000 mg L-tyrosin) 5-hydroxytriptophan (5-HTP) and 500 mg cysteine (Dr Daniel capsule for gray hair) in the intervention groups; or oral placebo (glucose) in the control group for 6 consecutive months. Diet will be similar during the study period in all three groups. Adherence interventio

Three groups of normal men with gray hair (total=15) will receive daily oral L-tyrosin 500 mg or 3000 mg daily plus other essential elements including 50 mg (in cases on 500 mg L-tyrosin) or 300 mg (in cases on 3000 mg L-tyrosin) 5-hydroxytriptophan (5-HTP) and 500 mg cysteine (Dr Daniel capsule for gray hair) in the intervention groups; or oral placebo (glucose) in the control group for 6 consecutive months. Diet will be similar during the study period in all three groups. Adherence interventions will include monthly instruction in forms of oral and written material. Adherence to taking medication will be monitored by drug capsule return monthly.

Sponsors

Daniel F Fouladi
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
Male
Age
30 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

Normal men with gray hair.

Exclusion criteria

Secondary gray hair, malnutrition, taking other medications/supplements.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026